Spotlight on Drug Risks

| 01 September 2009

Efforts by the US Food and Drug Administration (FDA) to strengthen risk disclosure and management have intensified, causing the pharmaceutical industry to rethink its approach to advertising and promotional labeling. This article provides an overview of the recent intensified efforts by FDA related to risk information for pharmaceutical drug products.

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy